An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study.
D'Amico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, Moreira P, Silva I, Bosca-Watts M, Innocenti T, Dragoni G, Bezzio C, Zilli A, Furfaro F, Saibeni S, Chaparro M, García MJ, Michalopoulos G, Viazis N, Mantzaris GJ, Ellul P, Gisbert JP, Magro F, Peyrin-Biroulet L, Armuzzi A, Ungaro F, Danese S, Fiorino G, Allocca M.
D'Amico F, et al. Among authors: dal buono a.
Eur J Clin Invest. 2024 Nov;54(11):e14283. doi: 10.1111/eci.14283. Epub 2024 Jul 9.
Eur J Clin Invest. 2024.
PMID: 38979834